The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multi-center randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first line therapy for patients with advanced unresectable biliary tract cancer.
 
Vaibhav Sahai
Honoraria - Celgene; Halozyme; Merrimack; Newlink Genetics
Consulting or Advisory Role - Celgene
Research Funding - Agios (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Incyte (Inst)
 
Kent A. Griffith
No Relationships to Disclose
 
Muhammad Shaalan Beg
Consulting or Advisory Role - Celgene; Genentech/Roche; Guardant Health; Ipsen; Merrimack
Speakers' Bureau - Genentech/Roche; Ipsen
Research Funding - Agios (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Merck Serono (Inst)
 
Mark Zalupski
Research Funding - Halozyme; Newlink Genetics/Pharmatech; Oncomed